Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin S Rhee

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Open Forum Infectious Diseases|December 29, 2025
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA StudyOnyema Ogbuagu, Andrew Wiznia, Joseph P McGowan, et al.
Open Forum Infectious Diseases|July 10, 2024
Long-acting HIV Treatments: Study Design, Logistics, and AccessNicholas A Murdock, Nayri E Alajaji, Robin Schaefer, et al.
The New England Journal of Medicine|May 11, 2022
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionSorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, et al.
Annals of Internal Medicine|December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized StudyAmy E Colson, Gordon E Crofoot, Peter J Ruane, et al.
Nature|July 3, 2020
Clinical targeting of HIV capsid protein with a long-acting small moleculeJohn O Link, Martin S Rhee, Winston C Tse, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Open Forum Infectious Diseases|December 29, 2025
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA StudyOnyema Ogbuagu, Andrew Wiznia, Joseph P McGowan, et al.
Open Forum Infectious Diseases|July 10, 2024
Long-acting HIV Treatments: Study Design, Logistics, and AccessNicholas A Murdock, Nayri E Alajaji, Robin Schaefer, et al.
The New England Journal of Medicine|May 11, 2022
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionSorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, et al.
Annals of Internal Medicine|December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized StudyAmy E Colson, Gordon E Crofoot, Peter J Ruane, et al.
Nature|July 3, 2020
Clinical targeting of HIV capsid protein with a long-acting small moleculeJohn O Link, Martin S Rhee, Winston C Tse, et al.
Pageof 4